Skip to main content
Lir Life Sciences Corp. logo

Lir Life Sciences Corp. — Investor Relations & Filings

Ticker · SKNY ISIN · CA50206C1005 LEI · 894500GZQCXFABJI4496 CSE Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country CA Canada
Listing CSE SKNY

About Lir Life Sciences Corp.

https://lirlife.com

Lir Life Sciences Corp. is a biopharmaceutical company specializing in the development of next-generation therapies for obesity and metabolic disorders. The company's core focus is advancing treatment accessibility through innovative drug-delivery approaches, specifically developing transdermal and alternative GLP-1 solutions. These therapies are designed to be scalable, affordable, and accessible globally, aiming to reduce reliance on traditional injections. Lir Life Sciences targets regions with rising obesity rates and limited access to existing GLP-1 treatments, addressing a significant unmet need in the rapidly growing global market.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2026-04-29 English
News release - English.pdf
Regulatory Filings Classification · 35% confidence The document is a corporate news release announcing a Technology Development Collaboration Agreement between LIR Life Sciences and Resilience BioSciences. It is not a financial report (annual or interim), not an earnings release, not a proxy statement, not a dividend notice, not a share issuance or buyback, not a management or board change, and does not announce financing or M&A activity. It does not include detailed financial statements or regulatory stress test results. It is a standalone corporate announcement that does not fit any specific detailed filing category, making “Regulatory Filings (RNS)” the appropriate fallback.
2026-04-21 English
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document is a news release announcing the upcoming unaudited first quarter 2026 results and the Annual General and Special Meeting (AGM) of shareholders. It provides dates for the earnings announcement and the AGM, details about the conference call and webcast, and references to proxy materials available online. The document does not contain actual financial data or detailed report content but rather informs about the timing and logistics of these events. The document length is short (2922 characters), and it primarily serves as an announcement rather than the report itself. Therefore, it fits best as a Report Publication Announcement (RPA) or possibly a Regulatory Filing (RNS). However, since it announces the timing of the earnings release and AGM, the most appropriate classification is Report Publication Announcement (RPA).
2026-04-21 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a certification form under Canadian NI 52-109 for interim filings, not the interim report itself, nor an announcement of results, dividend, or management change. It does not match any specific category like earnings release, MD&A, or interim report. It is a regulatory certificate filing, so it falls under the general "Regulatory Filings" fallback category (RNS).
2026-04-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 78% confidence The document is a Form 52-109FV2 certification of interim filings by the CEO under NI 52-109. It contains no financial statements or MD&A text itself—only a regulatory compliance certificate. It is not the interim report (IR), MD&A (MDA), or any announcement of results or meetings. Therefore it best fits the generic “Regulatory Filings” category for miscellaneous required filings (RNS).
2026-04-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a Form 52-109FV2 certificate by the CEO certifying the accuracy and presentation of the interim financial report and interim MD&A for the period ended January 31, 2026. It is a regulatory-required certification form attached to interim filings rather than the actual interim report or MD&A. There is no specific category for certification forms under NI 52-109, so this falls under the general Regulatory Filings category as a miscellaneous regulatory submission.
2026-04-02 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.